These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 32578225)

  • 1. Model-Aided Adults-to-Children Pharmacokinetic Extrapolation and Empirical Body Size-Based Dosing Exploration for Therapeutic Monoclonal Antibodies-Is Allometry a Reasonable Choice?
    Xu Y; Langevin BA; Zhou H; Xu Z
    J Clin Pharmacol; 2020 Dec; 60(12):1573-1584. PubMed ID: 32578225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A guide to rational dosing of monoclonal antibodies.
    Bai S; Jorga K; Xin Y; Jin D; Zheng Y; Damico-Beyer LA; Gupta M; Tang M; Allison DE; Lu D; Zhang Y; Joshi A; Dresser MJ
    Clin Pharmacokinet; 2012 Feb; 51(2):119-35. PubMed ID: 22257150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of human pharmacokinetics of therapeutic monoclonal antibodies from simple allometry of monkey data.
    Oitate M; Masubuchi N; Ito T; Yabe Y; Karibe T; Aoki T; Murayama N; Kurihara A; Okudaira N; Izumi T
    Drug Metab Pharmacokinet; 2011; 26(4):423-30. PubMed ID: 21606605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of Weight Thresholds for Pediatric Patients to Use Adult Dosage of Therapeutic Monoclonal Antibodies.
    Yang N; Xu MC; Yao Z
    J Clin Pharmacol; 2019 Oct; 59(10):1309-1318. PubMed ID: 31050000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The integration of allometry and virtual populations to predict clearance and clearance variability in pediatric populations over the age of 6 years.
    Edginton AN; Shah B; Sevestre M; Momper JD
    Clin Pharmacokinet; 2013 Aug; 52(8):693-703. PubMed ID: 23588537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetic properties of infliximab in children and adults with Crohn's disease: a retrospective analysis of data from 2 phase III clinical trials.
    Fasanmade AA; Adedokun OJ; Blank M; Zhou H; Davis HM
    Clin Ther; 2011 Jul; 33(7):946-64. PubMed ID: 21741088
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Linear pharmacokinetic parameters for monoclonal antibodies are similar within a species and across different pharmacological targets: A comparison between human, cynomolgus monkey and hFcRn Tg32 transgenic mouse using a population-modeling approach.
    Betts A; Keunecke A; van Steeg TJ; van der Graaf PH; Avery LB; Jones H; Berkhout J
    MAbs; 2018 Jul; 10(5):751-764. PubMed ID: 29634430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population Pharmacokinetics and Exposure-Response Modeling Analyses of Golimumab in Children With Moderately to Severely Active Ulcerative Colitis.
    Xu Y; Adedokun OJ; Chan D; Hu C; Xu Z; Strauss RS; Hyams JS; Turner D; Zhou H
    J Clin Pharmacol; 2019 Apr; 59(4):590-604. PubMed ID: 30536638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population pharmacokinetic analysis of sifalimumab from a clinical phase IIb trial in systemic lupus erythematosus patients.
    Zheng B; Yu XQ; Greth W; Robbie GJ
    Br J Clin Pharmacol; 2016 May; 81(5):918-28. PubMed ID: 26659791
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A workflow example of PBPK modeling to support pediatric research and development: case study with lorazepam.
    Maharaj AR; Barrett JS; Edginton AN
    AAPS J; 2013 Apr; 15(2):455-64. PubMed ID: 23344790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fixed dosing versus body size-based dosing of monoclonal antibodies in adult clinical trials.
    Wang DD; Zhang S; Zhao H; Men AY; Parivar K
    J Clin Pharmacol; 2009 Sep; 49(9):1012-24. PubMed ID: 19620385
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative prediction of human pharmacokinetics for monoclonal antibodies: retrospective analysis of monkey as a single species for first-in-human prediction.
    Dong JQ; Salinger DH; Endres CJ; Gibbs JP; Hsu CP; Stouch BJ; Hurh E; Gibbs MA
    Clin Pharmacokinet; 2011 Feb; 50(2):131-42. PubMed ID: 21241072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data: what have we learned?
    Deng R; Iyer S; Theil FP; Mortensen DL; Fielder PJ; Prabhu S
    MAbs; 2011; 3(1):61-6. PubMed ID: 20962582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of Quantitative Clinical Pharmacology in Pediatric Approval and Labeling.
    Mehrotra N; Bhattaram A; Earp JC; Florian J; Krudys K; Lee JE; Lee JY; Liu J; Mulugeta Y; Yu J; Zhao P; Sinha V
    Drug Metab Dispos; 2016 Jul; 44(7):924-33. PubMed ID: 27079249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multistep Unified Models Using Prior Knowledge for the Prediction of Drug Clearance in Neonates and Infants.
    Tegenge MA; Mahmood I; Jiang Z; Forshee R
    J Clin Pharmacol; 2018 Jul; 58(7):877-884. PubMed ID: 29489016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Retrospective Evaluation of Allometry, Population Pharmacokinetics, and Physiologically-Based Pharmacokinetics for Pediatric Dosing Using Clearance as a Surrogate.
    Wu Q; Peters SA
    CPT Pharmacometrics Syst Pharmacol; 2019 Apr; 8(4):220-229. PubMed ID: 30762304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of an integrated modelling and simulation approach to develop a simplified peginterferon alfa-2a dosing regimen for children with hepatitis C.
    Brennan BJ; Lemenuel-Diot A; Snoeck E; McKenna M; Solsky J; Wat C; Mallalieu NL
    Br J Clin Pharmacol; 2016 Apr; 81(4):658-66. PubMed ID: 26529640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Physiologically-Based Pharmacokinetic Modeling vs. Allometric Scaling for the Prediction of Infliximab Pharmacokinetics in Pediatric Patients.
    Malik PRV; Edginton AN
    CPT Pharmacometrics Syst Pharmacol; 2019 Nov; 8(11):835-844. PubMed ID: 31343836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population Pharmacokinetics of Brentuximab Vedotin in Adult and Pediatric Patients With Relapsed/Refractory Hematologic Malignancies: Model-Informed Hypothesis Generation for Pediatric Dosing Regimens.
    Suri A; Mould DR; Song G; Kinley J; Venkatakrishnan K
    J Clin Pharmacol; 2020 Dec; 60(12):1585-1597. PubMed ID: 32596842
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Initiation of Pediatric Clinical Trials for Coagulation Factors: Application of Pharmacokinetics and Allometry to First-in-Pediatric Dose Selection.
    Mahmood I
    J Clin Pharmacol; 2019 Jun; 59(6):829-834. PubMed ID: 30624769
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.